-
IntroducedJan 16, 2024
-
Passed Senate
-
Passed House
-
Signed into Law
An Act establishing the Alaska mental health and psychedelic medicine task force; and providing for an effective date.
Last Action See all actions
Senate • Mar 13, 2024: (S) COSPONSOR(S): TOBIN
Latest Bill Text See all bill texts
Official Summary/Bill Text
Comments on SB 166
Tweets
Whip Lists
Sponsors
Votes
Actions
- Mar 13, 2024 | Senate
- (S) COSPONSOR(S): TOBIN
- Mar 07, 2024 | Senate
- (S) JUD RPT CS 4DP 1NR NEW TITLE
- (S) DP: CLAMAN, GIESSEL, TOBIN, KIEHL
- (S) NR: KAUFMAN
- (S) FN1: ZERO(CED)
- (S) Referred to RULES
- Mar 06, 2024 | Senate
- (S) JUDICIARY at 01:30 PM BUTROVICH 205
- (S) Moved CSSB 166(JUD) Out of Committee
- Feb 26, 2024 | Senate
- (S) JUDICIARY at 01:30 PM BUTROVICH 205
- (S) Heard & Held
- (S) Minutes (SJUD)
- Feb 19, 2024 | Senate
- (S) L&C RPT CS 2DP 1NR NEW TITLE
- (S) NR: BJORKMAN
- (S) DP: DUNBAR, BISHOP
- (S) FN1: ZERO(CED)
- Feb 16, 2024 | Senate
- (S) LABOR & COMMERCE at 01:30 PM BELTZ 105 (TSBldg)
- (S) Moved CSSB 166(L&C) Out of Committee
- (S) Minutes (SL&C)
- Feb 05, 2024 | Senate
- (S) LABOR & COMMERCE at 01:30 PM BELTZ 105 (TSBldg)
- (S) Heard & Held
- (S) Minutes (SL&C)
- Jan 16, 2024 | Senate
- (S) Prefile released 1/8/24
- (S) Read the first time - REFERRALS
- (S) L&C, JUD
- (S) COSPONSOR(S): GRAY-JACKSON
Documents
- Sponsor Statement
- Senate Fiscal Note 1 by Commerce, Community & Econ. Dev. -- Fiscal impact: N (02/19/2024)
- SENATE JUDICIARY 3/6/2024 (Audio/Video)
- SENATE JUDICIARY 2/26/2024 (Minutes/Audio/Video)
- SENATE LABOR & COMMERCE 2/16/2024 (Minutes/Audio/Video)
- SENATE LABOR & COMMERCE 2/5/2024 (Minutes/Audio/Video)
- SJUD 5/6/2024 -- HB 228 T.A vs SB 166 N Summary of Differences 5.3.2024.pdf
- SJUD 3/6/2024 -- SB 166 Amendment 2.26.2024.pdf
- SJUD 2/26/2024 -- SB 166 Letter of Support - APRN Alliance 2.22.24.pdf
- SJUD 2/26/2024 -- SB 166 Testimony Received by 2.20.24.pdf
- SJUD 2/26/2024 -- SB 166 Research - Filter 2.15.24.pdf
- SJUD 2/26/2024 -- SB 166 Research - VETS Press Release Ibogaine 1.5.2024.pdf
- SJUD 2/26/2024 -- SB 166 Research - NIH Abstract 9.8.2023.pdf
- SJUD 2/26/2024 -- CSSB 166 ver P Summary of Changes 2.20.24.pdf
- SJUD 2/26/2024 -- SB 166 Sectional Analysis 2.20.2024.pdf
- SJUD 2/26/2024 -- CSSB 166 (L&C) ver P.pdf
- SJUD 2/26/2024 -- CSSB 166 ver P Sponsor Statement 2.20.2024.pdf
- SL&C 2/16/2024 -- SB166 Fiscal Note-DCCED-COMM 02.16.24.pdf
- SL&C 2/16/2024 -- SB166 Public Testimony Received by by sponsor 02.05.24.pdf
- SL&C 2/16/2024 -- SB166 Draft Proposed CS ver Y.pdf
- SL&C 2/16/2024 -- SB166 Public Testimony-Brooke Lavender 02.05.24.pdf
- SL&C 2/16/2024 -- SB166 Public Testimony-Tammi Lubitsh-White 02.15.24.pdf
- SL&C 2/16/2024 -- SB166 Summary of Changes ver S to CS ver Y 02.16.24.pdf
- SL&C 2/5/2024 -- SB166 Fiscal Note-DCCED-COMM 02.01.24.pdf
- SL&C 2/5/2024 -- SB166 Public Testimony-APRN Alliance 02.01.24.pdf
- SL&C 2/5/2024 -- SB166 ver S.pdf
- SL&C 2/5/2024 -- SB166 Sponsor Statement 1.29.2024.pdf
- SL&C 2/5/2024 -- SB166 Sectional Analysis 1.25.2024.pdf
- SL&C 2/5/2024 -- SB166 Research - VETS Press Release Ibogaine 1.5.2024.pdf
- SL&C 2/5/2024 -- SB166 Research - MAPS Press Release 12.13.2023.pdf
- SL&C 2/5/2024 -- SB166 Research - NIH Abstract 9.8.2023.pdf